Hussman Strategic Advisors Inc. Invests $1.93 Million in Alkermes plc (NASDAQ:ALKS)

Hussman Strategic Advisors Inc. purchased a new stake in shares of Alkermes plc (NASDAQ:ALKS) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 67,200 shares of the company’s stock, valued at approximately $1,933,000.

Other hedge funds also recently bought and sold shares of the company. Venturi Wealth Management LLC purchased a new stake in Alkermes during the fourth quarter valued at $25,000. Blue Trust Inc. raised its stake in Alkermes by 2,231.5% during the fourth quarter. Blue Trust Inc. now owns 1,702 shares of the company’s stock valued at $49,000 after purchasing an additional 1,629 shares in the last quarter. Archer Investment Corp raised its stake in Alkermes by 28.6% during the third quarter. Archer Investment Corp now owns 4,500 shares of the company’s stock valued at $126,000 after purchasing an additional 1,000 shares in the last quarter. KBC Group NV raised its stake in Alkermes by 18.8% during the third quarter. KBC Group NV now owns 4,890 shares of the company’s stock valued at $137,000 after purchasing an additional 774 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in Alkermes by 17.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,956 shares of the company’s stock valued at $164,000 after purchasing an additional 904 shares in the last quarter. Hedge funds and other institutional investors own 95.21% of the company’s stock.

Alkermes Stock Performance

NASDAQ ALKS opened at $35.84 on Thursday. The company has a market capitalization of $5.83 billion, a price-to-earnings ratio of 16.52, a price-to-earnings-growth ratio of 2.04 and a beta of 0.49. The company’s 50-day simple moving average is $30.60 and its two-hundred day simple moving average is $28.93. Alkermes plc has a one year low of $22.90 and a one year high of $36.45.

Alkermes (NASDAQ:ALKS) last issued its quarterly earnings data on Wednesday, February 12th. The company reported $0.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.81 by $0.11. Alkermes had a net margin of 23.57% and a return on equity of 30.80%. Equities analysts expect that Alkermes plc will post 1.43 earnings per share for the current fiscal year.

Insider Transactions at Alkermes

In related news, EVP Craig C. Hopkinson sold 9,221 shares of Alkermes stock in a transaction that occurred on Thursday, December 5th. The shares were sold at an average price of $31.50, for a total value of $290,461.50. Following the completion of the sale, the executive vice president now directly owns 59,730 shares in the company, valued at $1,881,495. This trade represents a 13.37 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Cato T. Laurencin sold 2,691 shares of Alkermes stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $31.85, for a total transaction of $85,708.35. Following the completion of the sale, the director now owns 23,013 shares of the company’s stock, valued at $732,964.05. This trade represents a 10.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 323,608 shares of company stock valued at $10,854,725 in the last 90 days. Insiders own 4.89% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on ALKS shares. The Goldman Sachs Group upped their price target on shares of Alkermes from $30.00 to $32.00 and gave the company a “buy” rating in a research note on Friday, February 14th. Stifel Nicolaus raised shares of Alkermes from a “hold” rating to a “buy” rating and increased their target price for the company from $25.00 to $36.00 in a research note on Tuesday, November 5th. Mizuho increased their target price on shares of Alkermes from $35.00 to $40.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. StockNews.com raised shares of Alkermes from a “buy” rating to a “strong-buy” rating in a research note on Thursday, February 13th. Finally, HC Wainwright reissued a “neutral” rating and issued a $46.00 target price on shares of Alkermes in a research note on Thursday, February 13th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Alkermes currently has a consensus rating of “Moderate Buy” and a consensus price target of $37.25.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.